-
Preliminary clinical results of innovative TCR immunotherapy combination for treating melanoma are positive
Time of Update: 2021-12-03
Recently, Immunocore announced that it will demonstrate its T-cell receptor therapy tebentafusp combined with PD-L1 inhibitor durvalumab and/or CTLA4 inhibitor tremelimumab at the 36th annual meeting of the Society for Cancer Immunotherapy (SITC) in the treatment of metastatic skin melanoma (MCM) Phase 1b clinical trial results .
-
Johnson & Johnson's Ebola vaccine program safely induces strong immune responses in healthy and HIV adults
Time of Update: 2021-12-03
Recently, data from a study published in the journal PLOS Medicine in the United States showed that Johnson & Johnson (JNJ)'s Ebola vaccine program (2-dose immunization)-Zabdeno® (Ad26.
-
New liquid biopsy technology: a urine test to predict the risk of cancer progression within 5 years
Time of Update: 2021-12-03
After their comparison, they found that when the patient was classified as PUR 4 risk by urine test, a large number of grade 4 cancer cells would appear in samples still at Gleason 2-3 level.
-
It is expected to control hypertension with one shot in half a year!
Time of Update: 2021-12-03
On November 8, 2021, Alnylam Pharmaceuticals announced the initiation of a global phase 2 clinical trial to evaluate RNAi therapy zilebesiran (formerly ALN-AGT) in hypertensive patients whose blood pressure cannot be adequately controlled by standard antihypertensive drug therapy.
-
AbbVie's oral JAK1 inhibitor Rinvoq in the treatment of moderate to severe RA shows long-term sustained response
Time of Update: 2021-12-03
AbbVie recently announced the evaluation of an oral JAK1 inhibitor Rinvoq (upadacitinib, upatinib, 15 mg, once daily) for the treatment of patients with rheumatoid arthritis (RA) in the Phase 3 SELECT-BEYOND clinical trial of a post-mortem analysis New data .
-
New non-invasive detection system can realize long-term blood lipid management of patients
Time of Update: 2021-12-02
Lowering the level of low-density lipoprotein cholesterol can significantly reduce the risk of atherosclerotic cardiovascular disease and death .
Therefore, there is an urgent clinical need for a method that can be used for long-term blood lipid management in patients with cardiovascular diseases .
-
Under the froth of the "Innovative Era", the "involution" of biological products is becoming fierce
Time of Update: 2021-12-02
This article focuses on the analysis of the clinical trial information of biological products registered in the "Annual Report on the Status of Clinical Trials of New Drug Registration in China (2020)" .
-
It is expected to be the first innovative hepatitis D therapy approved by the FDA, Gilead submits a regulatory application
Time of Update: 2021-12-02
On November 19, 2021, Gilead Sciences announced that it has submitted a biologics license application (BLA) for bulevirtide to the US FDA .
This is a potential "first-in-class" hepatitis therapy for the treatment of adult patients with chronic hepatitis D virus (HDV) infection with compensatory disease .
-
Janssen's potential "first-in-class" dual-antibody therapy starts clinical trials in China
Time of Update: 2021-12-02
According to the Chinese Drug Clinical Trial Registration and Information Disclosure Platform website, the launch in China this time is a project carried out in subjects with relapsed or refractory multiple myeloma, about the 1/2 phase of talentamab and its first use in humans.
-
The second case in the world: self-healing of AIDS without drug treatment is not a special case!
Time of Update: 2021-12-02
Researcher Xu Yu from the Lagen Institute mentioned, “Like the first HIV-infected person reported by Nature in 2020 who healed without any treatment-the'San Francisco patient', both patients have special lethal T Cells .
-
Three powers join forces to treat fatal brain tumors, innovative tumor electric field therapy re-expands anti-cancer potential
Time of Update: 2021-12-02
picture▲The mechanism of tumor electric field therapy (picture source: Novocure official website)The Phase 2 trial enrolled 25 adult patients with glioblastoma (median age 61 years), and the median follow-up time was 14.
-
Treat diabetes! CRISPR-edited cell replacement therapy enters the clinic
Time of Update: 2021-12-02
On November 16, 2021, ViaCyte and CRISPR Therapeutics jointly announced that Health Canada has approved a clinical trial application (CTA) for CRISPR gene-edited stem cell-derived therapy VCTX210 for the treatment of type 1 diabetes (T1D) .
-
NMPA released the results of the national medical device supervision and sampling: 26 batches of products did not meet the standard requirements
Time of Update: 2021-12-02
In order to strengthen the supervision and management of medical devices and ensure the quality, safety and effectiveness of medical device products, the National Medical Products Administration organized a random inspection of the product quality of 14 varieties including semiconductor laser treatment machines, high-frequency surgical equipment, and synthetic resin teeth, with a total of 26 batches ( Taiwan) The product does not meet the standard requirements .
-
Genetron Health publishes a patented algorithm for UVC mutation recognition in Oxford Bioinformatics Bulletin
Time of Update: 2021-12-02
Reference materials:[1] Xiaofei Zhao, Allison C Hu, Sizhen Wang, Xiaoyue Wang, Calling small variants using universality with Bayes-factor-adjusted odds ratios, Briefings in Bioinformatics, 2021Safe Harbor StatementThis press release contains Genetron Health's future expectations, plans and forward-looking statements, which are subject to corresponding risks and uncertainties, which may cause actual results to differ from the expectations described in the forward-looking statements .
-
The latest data from the Phase II clinical trial of Sagimet's partner, Sagimet, shows that ASC40 (TVB-2640) has a positive effect on NASH patients in China and the United States
Time of Update: 2021-12-02
(Hong Kong Stock Exchange code: 1672) today announced that its partner Sagimet Biosciences has announced TVB-2640 (Gere code: ASC40) The latest data from the Phase II clinical trial (FASCINATE-1) in patients with non-alcoholic steatohepatitis (NASH) in China and the United States .
-
The CREB binding protein (CBP)/β-catenin inhibitor E7386 jointly developed by Eisai and PRISM BioLab achieved clinical POC (proof of concept)
Time of Update: 2021-12-02
Based on the results of the POC, Eisai initiated a phase Ib/II clinical trial of E7386 combined with anti-PD-1 therapy pembrolizumab in the treatment of solid tumors (Study 201) in Japan .
-
Harvard blockbuster study: Vitamin D and fish oil reduce the risk of autoimmune diseases by 25% to 30%
Time of Update: 2021-12-02
In more than 5 years, the VITAL study conducted a rigorous placebo-controlled trial to explore the preventive effects of omega-3 and vitamin D supplementation on related diseases, including the independent and synergistic effects of these two nutritional supplements .
-
Cellectis another spot-type CAR-T announces positive preclinical data for the treatment of solid tumors
Time of Update: 2021-12-02
Article source: Medical Rubik's Cube ProAuthor: Bai LuOn November 12, at the annual meeting of the Society for Cancer Immunotherapy (SITC), Cellectis announced the first allogeneic CAR-T cell candidate product UCARTMESO targeting Mesothelin (MSLN) for the treatment of pancreatic cancer and mesothelioma.
-
"Nature" published a paper revealing a new mechanism for disease-causing bacteria to evade innate immunity
Time of Update: 2021-12-02
Liu Xiaoyun of Peking University School of Basic Medicine published an important new development in the top academic journal Nature, revealing a new mechanism by which pathogens inhibit host cell pyrolysis.
1038/s41586-021-04020-1[2] Shao Feng/Liu Xiaoyun’s team reveals a new mechanism by which pathogens inhibit host cell pyrolysis-a new protein post-translational modification Retrieved Nov.
-
Research reveals why elderly people are susceptible to new crowns
Time of Update: 2021-12-02
They found that the level of the protein increases with age, comorbid diseases and infections, and it is an effective stimulus for the new coronavirus to infect cells through the ACE2 receptor .
